Cocaine Use Clinical Trial
Official title:
L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder
Verified date | October 2019 |
Source | University of Maryland, Baltimore |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cocaine continues to be one of the most widely used substances of abuse around the world. In
the US, an estimated 1.4 million individuals (0.5%) > 12 years were current (past month)
cocaine users in 2011. Currently, no FDA-approved pharmacologic treatments are available for
cocaine addiction; thus, this remains a serious public health problem without an effective
pharmacological treatment. A promising lead towards an effective treatment comes from a
recent finding that pretreatment with oral l-tetrahydropalmitine (l-THP) in rats attenuated
the cocaine seeking associated with a cocaine challenge, while having no motor effects. This
finding stimulated our group to test the pharmacokinetics and safety of l-THP in a phase I
study of people with cocaine use. Preliminary findings show l-THP is safe and well tolerated
in cocaine users, with no adverse interactions with cocaine.
This study will test the efficacy and safety of l-THP for abstinence in those with cocaine
addiction in a phase II pilot study (N=24). Secondarily, we will examine the effects of these
medications on craving.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - men or non-pregnant/non-nursing women between the ages of 18 and 50 years - meeting criteria for DSM-5 cocaine use disorder - self-reported cocaine use (intranasal, IV or smoked) averaging at least weekly for the prior six months positive urine drug test for cocaine in the prior month - HIV seronegative - EKG without clinically significant abnormality - normal blood pressure (systolic: 90-140 mmHg; diastolic: 50-90 mmHg) and resting heart rate (60-90 bpm) - ability to adhere to the study restrictions and examination schedule - women with reproductive potential must agree to the use of one of the following birth control methods (oral contraceptives, condom with spermicide, diaphragm, or intrauterine device) during the study and for 2 weeks after last medication dose. Exclusion Criteria: - participation in any investigational drug trial or clinical drug trial within 45 days before study entry - history of clinically significant adverse reaction or hypersensitivity to cocaine or l-THP - inability to communicate or co-operate with the investigators - currently taking any prescribed psychoactive medication, e.g., anti- depressant, anti-psychotic, or mood stabilizer - current clinically significant medical problem that might interfere with safe study participation. This includes pheochromocytoma, untreated hyperthyroidism, dehydration, fever, coronary artery disease, uncorrected congenital heart defect, seizures, electrolyte imbalance, uncontrolled diabetes mellitus, porphyria variegate, superventricular tachycardia, atrial fibrillation, cardiomyopathy, or uncontrolled hypertension. - current Axis I Major Depression, Schizophrenia, or Bipolar Disorder. - score below 10/12 on the Evaluation to Sign Consent (ESC) |
Country | Name | City | State |
---|---|---|---|
United States | Maryland Psychiatric Research Center | Catonsville | Maryland |
Lead Sponsor | Collaborator |
---|---|
University of Maryland, Baltimore | National Institute on Drug Abuse (NIDA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | We will assess abstinence to cocaine as the outcome | We will measure cocaine and its metabolite by urine drug test to assess for abstinence. | 8 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05974202 -
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
|
Phase 2 | |
Recruiting |
NCT04927143 -
Encouraging Abstinence Behavior in a Drug Epidemic
|
Phase 2 | |
Active, not recruiting |
NCT05809453 -
Intranasal Cocaine and Temperature Regulation During Exercise
|
Phase 1/Phase 2 | |
Completed |
NCT01851473 -
Interactions Between Intravenous Cocaine and Acetazolamide or Quinine
|
Phase 1 | |
Completed |
NCT04061941 -
Change in Cognitive Function in Stimulant Users
|
||
Completed |
NCT01631383 -
Pharmacokinetic and Safety Evaluation of L-tetrahydropalmatine (l-THP) With Cocaine Exposure in People With a History of Cocaine Use
|
Phase 1 | |
Withdrawn |
NCT01222806 -
Pilot Study of Repetitive Transcranial Magnetic Stimulation in Cocaine Craving
|
Phase 1 | |
Recruiting |
NCT06177860 -
Clinical and Atherosclerotic Characteristics of Patients With ACS Associated With Cocaine Use
|
||
Completed |
NCT04418076 -
Project SMART Automated Pillbox Study
|
N/A | |
Recruiting |
NCT05766631 -
Treating Polysubstance Use Using a Novel Digital Technology
|
Phase 3 | |
Enrolling by invitation |
NCT05704764 -
Using the Ending Self-Stigma Intervention to Reduce Internalized Stigma Among People Living With HIV Who Use Substances
|
N/A | |
Not yet recruiting |
NCT06045793 -
Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)
|
Phase 2 | |
Not yet recruiting |
NCT05824221 -
Effect of rTMS on Neurotrophines Levels in CUD
|
N/A |